Subscribe

Nicholas Brownstone, MD: Achieving Long-Term Success in Psoriasis

Patient Cases
Dr. Brownstone discusses the place of risankizumab in the psoriasis and psoriatic arthritis treatment landscape. He discusses risankizumab’s durable response, infrequent dosing, and favorable long-term and short-term safety profiles. Dr. Brownstone references the UltIMMa-1 (NCT02684370) and UltIMMa-2 (NCT02684357) trials, which demonstrated the superior efficacy of risankizumab vs placebo and ustekinumab in this patient population. Additionally, he cites a recent anecdotal case detailing one of his patient’s positive experiences with risankizumab.

More JCAD Podcasts:

Joseph Fakhoury, MD: Special Considerations in Severe Alopecia Areata

Jeffrey Cohen, MD, MPH: Treating Psoriasis in High-Impact Sites

Tina Bhutani, MD, MAS, FAAD: Use of Spesolimab for Generalized Pustular Psoriasis

Bruce Strober, MD, PhD, FAAD: Providing Care With Risankizumab in Psoriasis

James Del Rosso, DO, and David Cotter, MD, PhD: Clinical Management of Conjunctivitis, Erythema, and Arthralgia in AD

Ted Lain, MD, MBA: Long-Term Results of Deuruxolitinib for Alopecia Areata

Amy McMichael, MD: Eight-Week Outcomes With Deuruxolitinib in Alopecia Areata

Graham Litchman, DO, MS: Understanding Long-Term Treatment Success in a Patient With Psoriasis